No Shinkei Geka. Neurological Surgery[JOURNAL]
Sun
200 papers
[Intrasaccular Device "WEB" Expands Indications for Aneurysm Treatment: Details and Future Developments].
Takigawa T
No Shinkei Geka · 2026 Jan · PMID 41700039 · Publisher ↗
Endovascular treatment for wide-neck bifurcation aneurysms has improved with device advancements, yet it remains technically challenging. The Woven EndoBridge (WEB) device is establishing itself as a treatment capable of...
Endovascular treatment for wide-neck bifurcation aneurysms has improved with device advancements, yet it remains technically challenging. The Woven EndoBridge (WEB) device is establishing itself as a treatment capable of achieving both high efficacy and safety for these types of aneurysms. Future advancements in WEB are expected to broaden its applicability to smaller and lower-lying aneurysms, positioning it as an increasingly important treatment option for cerebral aneurysms.
[Coating Technology for Flow Diverter Devices].
Ishihara K
No Shinkei Geka · 2026 Jan · PMID 41700038 · Publisher ↗
Flow diverter (FD) devices have become a standard treatment for cerebral aneurysms. FDs are braided metallic stents designed to redirect blood flow, thereby reducing intra-aneurysmal pressure, promoting vascular remodeli...
Flow diverter (FD) devices have become a standard treatment for cerebral aneurysms. FDs are braided metallic stents designed to redirect blood flow, thereby reducing intra-aneurysmal pressure, promoting vascular remodeling, and preventing rupture. Although their safety and efficacy are well established, thromboembolic risk still requires dual antiplatelet therapy (DAPT). However, DAPT increases hemorrhagic risk and mortality, even when intracranial circulation is not directly affected. To address this limitation, recent FD designs focus on improving surface biocompatibility through chemical modifications that suppress coagulation and thrombosis. The long-term objective is to enable treatment under single antiplatelet therapy, which may broaden use to ruptured aneurysms where DAPT is contraindicated. Coating metallic devices with functional polymers has been investigated to modulate biological responses, including coagulation and endothelialization. Among these materials, 2-methacryloyloxyethyl phosphorylcholine (MPC) polymers, inspired by the phospholipid structure of cell membranes, demonstrate strong hemocompatibility and clinical reliability. This article reviews the interfacial properties of MPC polymers, their applications in medical devices, and their recent integration into an FD device.
[Paradigm Shift in Intracranial Aneurysm Management: Clinical Application of Flow Diverters in Japan].
Sakata H, Endo H
No Shinkei Geka · 2026 Jan · PMID 41700037 · Publisher ↗
Endovascular treatment of large, wide-necked intracranial aneurysms has been challenged by high recurrence rates following coil embolization. Flow diverters, designed to redirect blood flow away from the aneurysm sac and...
Endovascular treatment of large, wide-necked intracranial aneurysms has been challenged by high recurrence rates following coil embolization. Flow diverters, designed to redirect blood flow away from the aneurysm sac and promote thrombosis and vessel wall reconstruction, have transformed therapeutic strategies. These devices, characterized by high mesh density compared to conventional stents, have become cornerstones in aneurysm management. Since the approval of the Pipeline device in 2008, multiple flow diverters have been developed worldwide; clinical use in Japan began in 2015, with expanded indications after 2020. Currently, Pipeline Flex with Shield Technology, FRED X, and Surpass Evolve are available domestically, each with distinct structural features, deployment characteristics, and antithrombotic properties. This article provides an overview of their differences, focusing on device selection, deployment techniques, and clinical applicability. By integrating device-specific considerations with structured preoperative planning, flow-diverter therapy offers a paradigm shift in treating complex aneurysms, thereby expanding options for cases resistant to conventional interventions.
[Neck Bridge Stent].
Arimura K
No Shinkei Geka · 2026 Jan · PMID 41700036 · Publisher ↗
Neck-bridge stents (NBS) play an essential role in the endovascular treatment of wide-neck intracranial aneurysms despite the increasing use of flow diverters and intrasaccular devices. Currently available NBS in Japan i...
Neck-bridge stents (NBS) play an essential role in the endovascular treatment of wide-neck intracranial aneurysms despite the increasing use of flow diverters and intrasaccular devices. Currently available NBS in Japan include the Enterprise VRD 2, LVIS/LVIS Jr, and Neuroform Atlas, each with distinct structural characteristics that influence deployment techniques and clinical applications. Laser-cut stents offer easier deployment and the ability to be resheathed, whereas braided stents provide higher mesh density and enhanced flow modification. Open-cell and closed-cell designs further determine vessel wall apposition and navigability in tortuous anatomies. Stent-assisted coiling can be performed using jailing or trans-cell techniques, each requiring careful microcatheter control to prevent coil protrusion or catheter kickback. Understanding the mechanical properties of each device allows clinicians to select the most appropriate stent based on aneurysm morphology, vessel tortuosity, and the need for flow modification or branch preservation. The enterprise VRD 2 is advantageous for straightening effects and ease of placement, LVIS is suitable for high-flow modification and tight neck coverage, and the Neuroform Atlas offers excellent conformability in bifurcation or highly curved vessels. This review summarizes the fundamental characteristics of NBS and provides practical insights for their optimal application in contemporary aneurysm treatment.
[Coil Embolization Strategy Based on Aneurysm Morphology: Roles of Framing, Filling, and Finishing Coils].
Takagaki M, Nakamura H, Ozaki T … +1 more , Kishima H
No Shinkei Geka · 2026 Jan · PMID 41700035 · Publisher ↗
Coil embolization remains an important technique for treating cerebral aneurysms, even with the development of new devices such as flow diverters and flow disruption systems. To achieve stable occlusion, it is important...
Coil embolization remains an important technique for treating cerebral aneurysms, even with the development of new devices such as flow diverters and flow disruption systems. To achieve stable occlusion, it is important to use coils in three steps: framing, filling, and finishing. The framing coil creates the initial support inside the aneurysm and helps prevent rupture during the procedure. Filling coils are then placed to pack the aneurysm densely and evenly. Finishing coils are used at the end to close the small space near the neck and reduce the risk of recurrence. As aneurysms vary in shape-simple, irregular, or very small-the optimal coil strategy differs from case to case. Selecting the appropriate type of coil for the aneurysm shape and catheter position is essential for both safety and effectiveness. This review explains practical considerations for each step and shows how aneurysm morphology can guide coil selection to improve treatment outcomes.
[Microcatheter User's Manual].
Nishihori M
No Shinkei Geka · 2026 Jan · PMID 41700034 · Publisher ↗
Although flow diverter stents are gaining prominence in unruptured aneurysms, intrasaccular coil embolization remains the fundamental strategy for treating ruptured cases. In this context, precise selection and manipulat...
Although flow diverter stents are gaining prominence in unruptured aneurysms, intrasaccular coil embolization remains the fundamental strategy for treating ruptured cases. In this context, precise selection and manipulation of microcatheters (MCs) are pivotal determinants of procedural success. This article provides a comprehensive overview of the mechanical properties of MCs-particularly the balance between proximal stiffness and distal flexibility-their specifications, and selection criteria for devices widely available in Japan, with a specific focus on manual shaping techniques. We present experimental data comparing the shape-memory capabilities and shape-retention durability of various commercially available MCs following heat-gun and steam processing. Furthermore, we introduce practical "spiral shaping" methods tailored for paraclinoid aneurysms with complex geometric axis misalignments, and discuss decision-making strategies for intraoperative MC repositioning to achieve optimal coil distribution. A thorough understanding of MC mechanics and mastery of appropriate shaping techniques are vital for neurointerventionists to ensure safe and effective treatment outcomes.
[Guide Catheters and Distal Access Catheters in Neuroendovascular Therapy: Structural Characteristics and Selection Strategies].
Fuga M
No Shinkei Geka · 2026 Jan · PMID 41700033 · Publisher ↗
Guiding and distal access catheters (DACs) play a fundamental yet often underrecognized role in neuroendovascular therapy by supporting device maneuverability, procedural stability, and vascular protection. Although atte...
Guiding and distal access catheters (DACs) play a fundamental yet often underrecognized role in neuroendovascular therapy by supporting device maneuverability, procedural stability, and vascular protection. Although attention frequently centers on microcatheters, coils, and flow diverters, procedural success depends on guiding system configuration and meticulous preoperative planning. This review summarizes structural characteristics and selection principles of guiding catheters and DAC from both practical and educational perspectives. Three factors-size, length, and stiffness-determine guiding catheter stability, navigability, and vascular safety. A rational selection process tailored to the vascular anatomy and treatment strategy was outlined, including the use of balloon-guiding catheters for proximal flow control and guiding sheaths that allow sheathless operation while reducing puncture-site complications. This section on DACs highlights their role in overcoming vessel tortuosity, improving distal support, and enhancing microcatheter control and reproducibility. Advances in thin-wall construction and graded flexibility have improved distal reach while preserving support, although potential risks, such as contrast-induced encephalopathy and vessel injury, warrant caution. Ultimately, selection of the optimal guiding system reflects not only technical preference but also procedural strategy and clinical judgment. Systematizing these principles transforms individual experiences into structured, teachable knowledge and promotes safer and more reproducible neuroendovascular practices.
[The "Essence" and "Devices" in Transradial Neurointervention].
Hanaoka Y
No Shinkei Geka · 2026 Jan · PMID 41700032 · Publisher ↗
Transradial neurointervention (TRN) benefits patients and neurointerventionalists. The radial artery is small in diameter and prone to vasospasm; thus, it must be handled gently from puncture to hemostasis. Ultrasound-gu...
Transradial neurointervention (TRN) benefits patients and neurointerventionalists. The radial artery is small in diameter and prone to vasospasm; thus, it must be handled gently from puncture to hemostasis. Ultrasound-guided puncture is recommended. Normal variations, such as the brachioradial artery or radial artery loop, should be considered. The size of the catheter system was selected based on radial artery diameter. The sheath-to-artery ratio must be ≤1, particularly with large-bore catheter systems or sheathless technique. The difficulty of TRN and system stability vary depending on the transradial approach side, aortic arch type, target vessel, including the common carotid and vertebral arteries, and proximal target vessel trajectory. The optimal system setup should be determined before TRN. Hemostasis should be performed using a hemostatic device, applying minimal compression and completing hemostasis within 120 min to minimize the risk of radial artery occlusion.
[Anterior Thalamic Deep Brain Stimulation Therapy Based on Functional Anatomy].
Ishizaki T, Maesawa S, Saito R
No Shinkei Geka · 2025 Nov · PMID 41362044 · Publisher ↗
Deep brain stimulation (DBS) targets the anterior nucleus of the thalamus (ANT), and has emerged as a promising treatment for drug-resistant epilepsy. ANT-DBS is thought to exert its antiepileptic effect by activating in...
Deep brain stimulation (DBS) targets the anterior nucleus of the thalamus (ANT), and has emerged as a promising treatment for drug-resistant epilepsy. ANT-DBS is thought to exert its antiepileptic effect by activating inhibitory interneurons in the cingulate gyrus, thereby modulating epileptic activity through the Papez circuit and default mode network, both major components of the limbic system. Among the ANT subnuclei, the anteroventral nucleus (AV) is considered the most promising stimulation site because of its extensive connectivity with the limbic system. However, direct visualization of the AV nucleus using MRI is challenging. In contrast, the ANT-mammillothalamic tract (MTT) junction is clearly identifiable on imaging, and serves as a practical landmark for targeting. There are two major surgical approaches for ANT-DBS: transventricular and extraventricular. Thus, the transventricular approach may offer superior electrode placement accuracy. As increasing evidence indicates that seizure outcomes are more closely related to the precise stimulation site than to stimulation parameters, image-guided targeting based on the ANT-MTT junction is considered critically important for optimizing clinical outcomes.
[Palliative Care for Pediatric Brain Tumors:Essential Skills for Neurosurgeons].
Mori N
No Shinkei Geka · 2025 Nov · PMID 41362043 · Publisher ↗
Pediatric brain tumors are the leading cause of cancer-related deaths in children, and cause unique suffering by degrading the neurological functions essential to a child's identity. Palliative care is no longer seen as...
Pediatric brain tumors are the leading cause of cancer-related deaths in children, and cause unique suffering by degrading the neurological functions essential to a child's identity. Palliative care is no longer seen as terminal care, but rather as a crucial approach to improve quality of life (QOL), which should integrated from the time of diagnosis alongside curative therapy. Effective symptom management is fundamental, addressing increased intracranial pressure with steroids, and pain via a stepwise approach using opioids, adjuvant analgesics, seizures, and swallowing difficulties through multidisciplinary collaboration. Palliative intent surgery, such as a cerebrospinal fluid shunt or tumor debulking, and palliative radiotherapy can provide significant symptom relief. There is also a growing desire for home-based care, which requires a seamless transition supported by a close collaboration between hospitals and community medical teams. This was achieved through pre-discharge conferences to share prognoses, specific emergency care plans, and 24-hour support. The principles of shared decision-making (SDM) and Advance Care Planning (ACP) are vital to ensure that care aligns with the patient and family values through ongoing dialogue. The neurosurgeon's role extends beyond technical procedures to coordinate comprehensive care and empower patients and their families throughout the course of illness.
[Fertility Preservation for Pediatric Brain Tumor Patients: Current Status and Challenges].
Takae S, Suzuki N
No Shinkei Geka · 2025 Nov · PMID 41362042 · Publisher ↗
Fertility preservation treatment is becoming increasingly popular in Japan, but very few pediatric brain tumor patients have undergone this treatment even though such tumors are relatively common and affected patients ar...
Fertility preservation treatment is becoming increasingly popular in Japan, but very few pediatric brain tumor patients have undergone this treatment even though such tumors are relatively common and affected patients are important candidates for fertility preservation. Fertility preservation treatments for girls include oocyte cryopreservation (OC) and ovarian tissue cryopreservation (OTC). However, OC requires transvaginal procedures and daily controlled ovarian stimulation, which can be difficult to implement, and OTC is still a new option, and there have been very few live births till now. For boys, sperm cryopreservation, including after testicular sperm extraction (TESE), is the only fertility preservation option. Among pediatric patients with brain tumors, boys are at higher risk of fertility loss (gonadal failure), especially those with germ cell tumors. Furthermore, more than half of the treatment protocols for atypical teratoid rhabdoid tumor or ependymoma have been shown to result in gonadal failure in both boys and girls. Currently, the reproductive outcomes of fertility preservation in pediatric brain tumor patients are unclear, and more cases need to be investigated.
[Neurocognitive Impairments after Pediatric Brain Tumor Treatment].
Nukui M
No Shinkei Geka · 2025 Nov · PMID 41362041 · Publisher ↗
With improved cure rates for pediatric brain tumors, attention has increasingly turned to enhancing quality of life after treatment. Children with brain tumors commonly develop cognitive impairment due to the combined ef...
With improved cure rates for pediatric brain tumors, attention has increasingly turned to enhancing quality of life after treatment. Children with brain tumors commonly develop cognitive impairment due to the combined effects of the tumor itself, radiation therapy, chemotherapy, surgical treatment, hydrocephalus, neurological complications, and predisposing factors. Patients undergoing pediatric brain tumor treatment are prone to localized cognitive deficits and generalized brain dysfunction, such as intellectual decline and fatigue. Difficulties arising from cognitive impairment often emerge during the late phase of treatment, thereby necessitating ongoing assessment. It is important to promote patient independence while recognizing developmental stages and prevent secondary impairments through appropriate assessment and support.
[Endocrine Complications and Their Management Following Treatment of Pediatric Brain Tumors].
Terada K, Ayuta K, Noguchi Y
No Shinkei Geka · 2025 Nov · PMID 41362040 · Publisher ↗
Advances in the treatment of pediatric brain tumors have markedly improved survival rates; however, long-term survivors still commonly experience delayed effects, particularly endocrine disorders. Growth hormone deficien...
Advances in the treatment of pediatric brain tumors have markedly improved survival rates; however, long-term survivors still commonly experience delayed effects, particularly endocrine disorders. Growth hormone deficiency, central hypothyroidism, gonadal dysfunction, including pubertal abnormalities, and central diabetes insipidus are the most common such complications. Their onset is influenced by tumor type, surgical intervention, and cranial irradiation. Survivors of craniopharyngioma commonly develop panhypopituitarism and hypothalamic obesity, whereas survivors of germ cell tumors frequently present with diabetes insipidus and pubertal disturbances. Patients with medulloblastoma, particularly those receiving craniospinal irradiation, are at high risk of growth hormone deficiency and multiple hormonal deficits. These endocrine complications may be progressive and asymptomatic in the early stages, thus underscoring the necessity for systematic follow-up. Lifelong surveillance is recommended, with evaluations conducted at 1, 5, 10, and 20 years after treatment, focusing on growth, puberty, thyroid and adrenal functions, and metabolic status. The transition from pediatric to adult care, fertility preservation, and the management of lifestyle-related diseases represent additional challenges. Comprehensive multidisciplinary follow-up is essential to ensure an optimal quality of life in pediatric brain tumor survivors.
[Rehabilitation for Children with Brain Tumors].
Yoshihashi M
No Shinkei Geka · 2025 Nov · PMID 41362039 · Publisher ↗
Pediatric brain tumors result in diverse neurological and functional impairments arising from both the tumor itself and its treatment, including surgery, radiotherapy, and chemotherapy. Advances in oncological therapies...
Pediatric brain tumors result in diverse neurological and functional impairments arising from both the tumor itself and its treatment, including surgery, radiotherapy, and chemotherapy. Advances in oncological therapies have improved long-term survival rates, creating an increasing need for comprehensive rehabilitation throughout the acute, recovery, and community phases. Rehabilitation must address motor, cognitive, swallowing, communication, and psychosocial challenges through a multidisciplinary and developmentally informed approach. The International Classification of Functioning, Disability, and Health framework provides a useful structure for integrating interventions targeting body functions, activities, and participation. Early intervention, developmental alignment, and environmental modification are essential to optimize outcomes and promote participation in daily life and education. Long-term follow-up is required, as late effects and higher-order cognitive dysfunction often emerge during growth and school-age years. Effective coordination among medical, educational, and social services is critical to ensure continuity of care, including transition and vocational support during adolescence and adulthood. Despite growing recognition of its importance, evidence-based rehabilitation protocols and interinstitutional collaboration remain limited. Further research is needed to standardize assessment and intervention practices, develop longitudinal care models, and establish networks linking oncology, rehabilitation, and community resources to support each child in achieving a meaningful and self-directed life.
[Key Points for Long-Term Follow-Up of Pediatric Brain Tumors].
Kiyotani C
No Shinkei Geka · 2025 Nov · PMID 41362038 · Publisher ↗
With the improvement in survival rates, the goal of pediatric oncology is to shift from improving survival rates to living with cancer and surviving in good health without serious late complications. The same is true for...
With the improvement in survival rates, the goal of pediatric oncology is to shift from improving survival rates to living with cancer and surviving in good health without serious late complications. The same is true for pediatric brain tumors. Depending on the individual patient's risk of late complications, long-term follow-up should be conducted with appropriate frequency, intensity, and structure to detect possible intervening factors and implement early intervention, with attention to possible endocrine complications, cognitive dysfunction, organ damage, vascular disease, and secondary tumors in the late stages. Addressing psychosocial issues specific to adolescents and young adults, as well as providing transition support and assistance with learning, employment, and independence difficulties associated with higher brain dysfunction, is also important. As neurosurgeons have limitations in dealing with these problems, it is necessary to establish a continuous and organic medical and support system for the patient's lifetime in collaboration with pediatrics, internal medicine, departments specializing in complication care, nurses, pharmacists, psychologists, rehabilitation centers, social workers, community medicine, and social welfare support. To this end, there appears to be an urgent need to train personnel involved in the long-term follow-up of pediatric brain tumors.
[Current Status and Future Perspectives of Clinical Trials for Diffuse Intrinsic Pontine Gliomas(DIPG)].
Suzuki T
No Shinkei Geka · 2025 Nov · PMID 41362037 · Publisher ↗
Diffuse intrinsic pontine glioma (DIPG) remains one of the most devastating pediatric central nervous system tumors, with a median survival of approximately 11 months despite decades of research. The identification of hi...
Diffuse intrinsic pontine glioma (DIPG) remains one of the most devastating pediatric central nervous system tumors, with a median survival of approximately 11 months despite decades of research. The identification of histone H3 K27M mutations marked a pivotal moment, leading to major advancements in understanding the molecular and epigenetic characteristics of these tumors. This discovery enabled molecular classification and provided a basis for the development of novel therapeutic strategies. In recent years, clinical trials have investigated molecular targeted agents and epigenetic modulators. Immunotherapeutic approaches, such as CAR-T cell therapy, have shown promising early results, whereas innovative drug delivery techniques, including convection-enhanced delivery and focused ultrasound, aim to overcome the challenges of the blood-brain barrier. Two major international registries, the International DIPG/DMG Registry (IDIPGR) and the European Society for Paediatric Oncology (SIOPE) DIPG/DMG Registry, play crucial roles in collecting comprehensive clinical data across multiple countries. The DIPG-2023 registry study was launched in Japan to collect prospective clinical, radiological, and molecular data systematically and to provide a high-quality external control cohort for future intervention trials. These collaborative efforts highlight a new era of DIPG/DMG research, offering cautious optimism for therapeutic progress in this historically refractory disease.
[Current Status and Prospects of Clinical Trials for Ependymoma].
Saito R, Taniguchi R
No Shinkei Geka · 2025 Nov · PMID 41362036 · Publisher ↗
Due to the sharp decline in the birth rate in Japan, a severe decline in pediatric brain tumor cases is expected. Ependymoma accounts for 5.4% of pediatric brain tumors, and due to its poor prognosis, understanding treat...
Due to the sharp decline in the birth rate in Japan, a severe decline in pediatric brain tumor cases is expected. Ependymoma accounts for 5.4% of pediatric brain tumors, and due to its poor prognosis, understanding treatment outcomes is crucial. However, in Japan, it is difficult to accurately understand treatment outcomes. Meanwhile, the World Health Organization's diagnostics have increasingly emphasized molecular diagnosis, making the establishment of a diagnostic system crucial. Although treatment guidelines have been published, due to trends in overseas clinical research, clinical practice does not necessarily conform to the 2022 guidelines. Amid changes in the medical system resulting from the rapid decline in the birthrate, this paper outlines the current status and outlook for clinical trials, both globally and in Japan.
[Current Status and Prospects of Clinical Trials for Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor].
Yamasaki K
No Shinkei Geka · 2025 Nov · PMID 41362035 · Publisher ↗
Medulloblastoma (MB) and atypical teratoid/rhabdoid tumors (ATRT) are highly aggressive pediatric brain tumors that necessitate multimodal therapy. Historically, treatment strategies in Japan have varied across instituti...
Medulloblastoma (MB) and atypical teratoid/rhabdoid tumors (ATRT) are highly aggressive pediatric brain tumors that necessitate multimodal therapy. Historically, treatment strategies in Japan have varied across institutions due to the absence of standardized protocols. The establishment of the Japan Children's Cancer Group (JCCG) enabled nationwide clinical trials based on central pathological and molecular diagnoses. In MB, intensification of chemotherapy has enabled a reduction in the craniospinal irradiation (CSI) dose while maintaining survival outcomes. The ongoing JCCG MB19 trial has incorporated molecular subgrouping into risk stratification and employed high-dose chemotherapy (HDC) to balance survival and neurocognitive preservation. However, early reports on radiation necrosis, particularly after proton therapy, highlighted new safety concerns that require careful evaluation. The treatment outcomes for ATRT have gradually improved with multimodal regimens; however, the prognosis remains poor, especially in metastatic cases. The JCCG AT20 trial attempted to standardize treatment approaches by combining platinum, sarcoma-based agents, and frequent intrathecal methotrexate, followed by HDC and local radiotherapy. CSI was administered only to older patients with metastases. Despite these advances, the absence of new therapeutic agents has limited further progress. In the case of medulloblastoma, it is crucial to further investigate dose modulation in local radiotherapy to find a balance between efficacy and toxicity. Additionally, in the case of ATRT; there is an urgent need for novel treatments, such as targeted therapies and immunotherapies.
[Tumor-Treating Fields Therapy for Pediatric Brain Tumors].
Ihara S
No Shinkei Geka · 2025 Nov · PMID 41362034 · Publisher ↗
Tumor-treating fields (TTF) are alternating electric fields applied to the brain through scalp arrays. Although TTF therapy has shown efficacy in adults with supratentorial high-grade glioma, its safety and efficacy in c...
Tumor-treating fields (TTF) are alternating electric fields applied to the brain through scalp arrays. Although TTF therapy has shown efficacy in adults with supratentorial high-grade glioma, its safety and efficacy in children remain unproven. Pediatric and adult high-grade gliomas differ genetically, but share clinical features that support trials in children. Recently, a pediatric case series using TTF has been reported, and a few prospective studies are underway. Because pediatric high-grade gliomas are rare and genetically diverse, these studies were designed as feasibility trials for various malignant brain tumors. Their primary goal is to confirm safety and feasibility; however, assessing the efficacy in each pediatric tumor subtype, including high-grade gliomas, is challenging. To address this issue, our clinical research team planned an investigator-initiated trial, specifically for pediatric supratentorial high-grade gliomas. The aim of this study was to expand the regulatory approval of TTF therapy in children by establishing safety and exploratory efficacy data supplemented by accumulated evidence in adults.
[Progress in Radiotherapy for Pediatric Brain Tumors].
Fuji H
No Shinkei Geka · 2025 Nov · PMID 41362033 · Publisher ↗
The molecular classification of pediatric brain tumors enables radiotherapy optimization. Proton-beam therapy and reirradiation offer clinical benefits. However, large-scale studies of these issues are ongoing. Once the...
The molecular classification of pediatric brain tumors enables radiotherapy optimization. Proton-beam therapy and reirradiation offer clinical benefits. However, large-scale studies of these issues are ongoing. Once the results are available, careful interpretation of new findings and consensus among expert oncologists will be essential to ensure the safe application of radiotherapy.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe